Bliss GVS Pharma appoints Rahul Adakmol as CEO and adds Santosh Parab as director

What Bliss GVS Pharma announced

Bliss GVS Pharma Ltd. disclosed the outcomes of its board meeting held on Friday, 3 July 2026. The board, acting on the recommendation of the Nomination and Remuneration Committee, approved three key changes in senior management and the board of directors.

Appointment of an Additional Director

The board appointed Mr. Santosh Parab (DIN: 01622988) as an Additional Director in the capacity of Non‑Executive, Non‑Independent Director. The appointment is effective from the date of the meeting, 3 July 2026. No further details on shareholding, tenure, or remuneration were disclosed in the filing.

Appointment of a New Chief Executive Officer

The board also approved the appointment of Mr. Rahul Adakmol as the new Chief Executive Officer (CEO) of Bliss GVS Pharma Ltd. The appointment will take effect on 15 July 2026. Concurrently, Mr. Narsimha Shibroor Kamath will step down from the CEO role with effect from the close of business on 14 July 2026. Mr. Kamath will retain his position as Managing Director of the company.

Key facts at a glance

Why this matters for investors

The leadership transition signals a strategic shift at the executive level. While the filing does not elaborate on the rationale, the appointment of a new CEO and the addition of a director may affect the company’s governance structure and operational oversight. Existing shareholders should note that the outgoing CEO will continue as Managing Director, ensuring continuity in day‑to‑day management. No immediate financial impact, such as share dilution or capital restructuring, is indicated.

Conclusion

Bliss GVS Pharma’s board has formally appointed Rahul Adakmol as CEO effective 15 July 2026 and added Santosh Parab as an additional director effective 3 July 2026. The former CEO, Narsimha Shibroor Kamath, will remain with the company as Managing Director. These changes were approved in a video‑conference board meeting and are now part of the company’s official corporate record.